Business · 17/11/2005Updated: 10/17/2026 · 1 min read
FDA to Reassign Numbers to Investigational New Drug Applications
Summary
The FDA is renumbering some investigational new drug applications submitted to the Center for Drug Evaluation and Research (CDER) to resolve duplicate numbers resulting from a 2003 consolidation of product oversight responsibilities.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →